Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Promyelocytic leukemia protein (PML) is a tumor suppressor and the primary structural component of PML nuclear bodies (PML-NBs), which are subnuclear organelles involved in various cellular processes (UniProt P29590). PML functions as a scaffold, recruiting numerous proteins to regulate apoptosis, cellular senescence, DNA damage repair, and antiviral responses (PubMed: 25324444). In Acute Promyelocytic Leukemia (APL), a chromosomal translocation typically fuses the PML gene with the Retinoic Acid Receptor Alpha (RARA) gene, creating the PML-RARA oncoprotein that disrupts normal PML-NB formation (NIH: NBK1404). Therapeutic agents like arsenic trioxide directly target the PML moiety of both the fusion protein and the wild-type protein, inducing their degradation and restoring cellular differentiation (Science, 2010, 328(5975):240-243). Beyond APL, wild-type PML is increasingly recognized for its role in solid tumors and as a potential target in viral infections and other malignancies (Nature Reviews Cancer, 2011, 11(11):797-811). The protein contains a tripartite motif (TRIM) consisting of a RING finger, two B-box zinc fingers, and a coiled-coil domain, which are essential for its multimerization and function (PubMed: 10644755). Loss of wild-type PML expression is observed in many human cancers, correlating with poor prognosis and tumor progression (PubMed: 15064413). Research continues to explore the therapeutic potential of modulating wild-type PML levels in non-APL contexts to exploit its tumor-suppressive properties.
Arsenic trioxide binds directly to the cysteine residues within the zinc fingers of the PML B2 domain, which triggers the recruitment of SUMO-conjugating enzymes, leading to hyper-SUMOylation of the protein. This modification facilitates the recruitment of the E3 ubiquitin ligase RNF4, resulting in the polyubiquitination and subsequent proteasomal degradation of the PML protein (Science, 2010, 328(5975):240-243; PubMed: 18408710).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Promyelocytic leukemia protein (PML) (PML).